Fig. 4: siMCJ treatment decreases liver steatosis, fibrosis and weight gain in a NASH model with metabolic disorders. | Nature Communications

Fig. 4: siMCJ treatment decreases liver steatosis, fibrosis and weight gain in a NASH model with metabolic disorders.

From: Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Fig. 4

Mice were placed on a high-fat, high-fructose diet (HF-HFD) for the duration of the study. Treatment with Invivofectamine-formulated siMCJ (n = 5) or PBS (n = 5) started after 4 months on HF-HFD (pre-treatment) and was provided weekly for a total of 5 weeks. Tissues were harvest 1 week after the last treatment. a Quantification of liver steatosis in H&E staining histological sections. b Representative images of liver lipids by Oil Red O staining. c Quantification of lipids from Oil Red O stained-liver sections. d Number of fibrotic areas per histological section of the liver as determined by Picro Sirius Red staining. e Representative images of Picro Sirius Red-stained liver sections. f Weight change after 6 weeks of treatment. *p < 0.05 siMCJ-treated compared with PBS control by one-way ANOVA or Student´s t test analysis. Error bars show standard deviation (SD) in all panels. Source data are provided as a Source Data file.

Back to article page